Stealth BioTherapeutics Corp. (MITO)
| Market Cap | 84.54M |
| Revenue (ttm) | 21.09M |
| Net Income (ttm) | -57.46M |
| Shares Out | 55.62M |
| EPS (ttm) | -1.24 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $1.52 |
| Previous Close | $1.62 |
| Change ($) | -0.10 |
| Change (%) | -6.17% |
| Day's Open | 1.37 |
| Day's Range | 1.30 - 1.52 |
| Day's Volume | 10,548,151 |
| 52-Week Range | 1.06 - 2.58 |
Will these 3 penny stocks be on your Thursday morning watchlist? The post Top Penny Stocks For Your Thursday Morning Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyS...
BOSTON, May 5, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies fo...
BOSTON, April 28, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies...
BOSTON, April 26, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies...
BOSTON, April 6, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies ...
BOSTON, March 31, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies ...
BOSTON, March 16, 2021 /PRNewswire/ -- Stealth BioTherapeutics (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for d...
BOSTON, March 2, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies f...
BOSTON, Feb. 23, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies f...
BOSTON, Jan. 7, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies fo...
BOSTON, Jan. 5, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies fo...
BOSTON, Dec. 9, 2020 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies fo...
BOSTON, Nov. 24, 2020 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) ("Stealth" or the "Company"), a clinical-stage biotechnology company focused on the discovery, development and commercia...
Stealth BioTherapeutics (MITO) CEO Reenie McCarthy on Q3 2020 Results - Earnings Call Transcript
BOSTON, Nov. 5, 2020 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies fo...
BOSTON, Nov. 4, 2020 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies fo...
Stealth BioTherapeutics to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020
BOSTON, Oct. 30, 2020 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies f...
BOSTON, Oct. 19, 2020 /PRNewswire/ -- Stealth BioTherapeutics (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for di...
BOSTON, Sept. 23, 2020 /PRNewswire/ -- Stealth BioTherapeutics (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for d...
BOSTON, Sept. 10, 2020 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies ...
Stealth BioTherapeutics Corp (MITO) CEO Reenie McCarthy on Q2 2020 Earnings Call Transcript
BOSTON, May 26, 2020 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies fo...
As of late, it has definitely been a great time to be an investor in Stealth BioTherapeutics Corp (MITO).
Stealth BioTherapeutics Corp (MITO) CEO Reenie McCarthy on Q1 2020 Results - Earnings Call Transcript
Stealth BioTherapeutics Corp (MITO) CEO Reenie McCarthy on Q4 2019 Results - Earnings Call Transcript
Stealth BioTherapeutics Corp. (NASDAQ: MITO) stock more than doubled on Tuesday after the company announced a critical update from the U.S.
Shares of Stealth BioTherapeutics MITO, -63.94% tumbled 63% after it said a late-stage trial for its investigational treatment of primary mitochondrial myopathy, a muscular disease caused by genetic mut...
Stealth BioTherapeutics Corp. (NASDAQ: MITO) shares were absolutely crushed on Friday after the firm announced results from its late-stage study in patients with primary mitochondrial myopathy.
About MITO
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's heredit... [Read more...]
| Industry Biotechnology | IPO Date Feb 15, 2019 |
| Stock Exchange NASDAQ | Ticker Symbol MITO |
Analyst Forecasts
According to 3 analysts, the average rating for MITO stock is "Buy." The 12-month stock price forecast is 3.33, which is an increase of 119.08% from the latest price.